Oncogenix BV – Redefining Precision Drug Discovery & Development
Oncogenix BV, headquartered in the Netherlands, is a next-generation biotechnology company which combines deep computational biology, advanced wet-lab capabilities, and translational research expertise to accelerate the discovery and development of novel therapies in Oncology, Autoimmune Disorders, and CNS diseases.
Our mission is to build breakthrough therapeutics that address high-unmet clinical needs—while delivering end-to-end preclinical services that empower biotech and pharma innovators worldwide.
Our Vision
To become Europe’s leading innovation hub for AI-enabled drug discovery, mechanistic biology, and translational development—turning complex biological data into clinically meaningful insights and life-changing therapies.
What We Do
Novel Drug Discovery & Development
We integrate multi-omics intelligence, mechanistic modelling, and wet-lab validation to drive new programs from idea to IND.
Our capabilities include:
Target identification & prioritization
Biomarker discovery & validation
Hit discovery and hit-to-lead optimization
Efficacy, PK/PD and mechanistic studies
IND-enabling preclinical development
We specialize in hard-to-treat cancers, autoimmune conditions, and complex CNS disorders.
AI-Integrated Mechanistic Biology Platform
Our cutting-edge data-driven AI platform powers our discovery engine with:
Multi-omics patient data mining
Disease sub-grouping & patient stratification
Novel target prediction
Drug response modelling
Rational drug combination design
Repurposing & repositioning of Phase II/III-failed molecules
Our platform identifies hidden biological drivers and reveals new therapeutic opportunities where conventional approaches fall short.
Advanced Preclinical Services
As part of our global network, we offer comprehensive in-vitro, in-vivo, and translational services, including:
2D/3D cell-based assays & organoid models
Immunology & autoimmune disease models
Oncology xenograft, orthotopic & PDX studies
CNS and neuroinflammation models
Toxicology & DMPK services
Why Oncogenix BV
Integrated AI + Wet-Lab Ecosystem
faster discovery cycles, higher predictive accuracy
End-to-End Capabilities
from molecular insights to IND-ready packages
Focus on High-Impact Diseases
oncology, autoimmune, CNS
Collaborative Approach
partnering with biotech, pharma & academic institutes
Our Collaboration Model
Oncogenix works through:
Co-development partnerships
Joint IP creation
Risk-sharing discovery models
Service-based preclinical programs
Licensing and out-licensing opportunities
We bring science, AI, and execution together to convert innovation into tangible therapeutic value.